ipsen
Phase 3 trials support expanded use of Dysport for migraine prevention
July 15, 2026Research and Development Dysport, ipsen, migraine prevention
Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport (abobotulinumtoxinA) for the prevention of …
Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
April 8, 2025Research and Development R&D, Rare Diseases, Scottish Medicines Consortium, ipsen, primary biliary cholangitis (PBC)
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS Scotland for the treatment of …
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
February 14, 2024Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …
Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
November 14, 2023Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients …
FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva
August 17, 2023Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen
Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …
FDA accepts Ipsen’s NDA for ultra-rare genetic disorder drug
June 1, 2021Manufacturing and Production EMA, FDA, FOP, NDA, ipsen
The FDA have accepted Ipsen’s New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist for the prevention …
Ipsen receives CHMP recommendation for Cabometyx in combination with Opdivo
March 1, 2021Sales and Marketing Cancer, EMA, ipsen
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Ipsen’s Cabometyx (cabozantinib) in combination with …
Ipsen appoints new Exec VP and Chief Medical Officer
January 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen, pharma
Ipsen has named Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs …
MHRA expands approval of Dysport for symptomatic treatment of focal spasticity of the upper limbs in paediatric cerebral palsy
January 6, 2020Sales and Marketing Dysport, MHRA, ipsen, pharma
Ipsen has secured an expansion in the UK to the existing label for Dysport (lemborexant), with the Medicines and Healthcare …
Ipsen shells out $1.31bn to acquire rare disease specialist Clementia Pharmaceuticals
February 25, 2019Sales and Marketing Clementia pharmaceuticals, acquisition, ipsen, rare disease
In a bid to boost its rare disease portfolio prospects, Ipsen has revealed its intention to acquire Clementia Pharmaceuticals, with …
Ipsen’s Cabometyx gains European approval in hepatocellular carcinoma
November 16, 2018Medical Communications, Sales and Marketing Cabometyx, carcinoma, ipsen, pharma. European Commission
Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular …
Ipsen appoints two leading R&D experts in bid to strengthen oncology arm
September 28, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, R&D, development, ipsen, oncology, research
French pharma firm Ipsen has announced the appointment of Dr. Yan Moore as Senior Vice President, Head of Oncology Therapeutic …
Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer
July 5, 2018Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …
Ipsen set to relocate North American HQ to Boston
June 11, 2018Medical Communications, Sales and Marketing biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen is set to join the ranks of a number of Boston-based biotechs, by setting up shop in Kendall Square. …
Ipsen receives European first-line approval for Cabometyx
May 17, 2018Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …
